INTRODUCTION {#S1}
============

Attachment and entry into a host cell is the first bottleneck virions encounter during infection. Virion entry requires efficient use of the host cell environment while evading cellular immune responses. Influenza A virus (FLUAV; *Orthomyxoviridae: Alphainfluenzavirus*), like all viruses, largely depends upon existing cellular machinery to successfully complete these initial stages of infection.

During the first step of infection, attachment, FLUAV hemagglutinin (HA) binds to the target cell via sialic acid linkages on host glycoproteins ([@R9]). Virions are internalized via receptor-mediated endocytosis and less frequently through an alternative macropinocytosis pathway ([@R29]; [@R7]). Once within endosomes, virions are trafficked toward the nucleus using the cytoskeletal components actin, dynein, and microtubules ([@R21]). The endosome matures and acidifies during cellular trafficking, and the virion interior is also acidified through the viral ion channel M2 ([@R38]). The low pH in the endosome causes conformational changes in HA that drive fusion of the viral and endosomal lipid membranes, whereas the low pH within the virion causes the viral matrix protein M1 to dissociate from the inner membrane of the viral envelope ([@R4]; [@R24]; [@R28]; [@R56]). Fusion of the two membranes releases a capsid-like viral core consisting of viral ribonucleoproteins (vRNPs) enclosed in an M1 shell-like structure into the cytoplasm. This complex engages the cellular aggresome and other host proteins to complete uncoating, and the released vRNPs are imported into the nucleus by cellular karyopherins ([@R2]; [@R31]; [@R32]; [@R36]; [@R51]). Once in the nucleus, a pioneering round of transcription occurs on the incoming vRNPs that initiates replication and secondary rounds of transcription of the viral genome.

High-throughput screening approaches have expanded our knowledge of specific cellular cofactors involved in FLUAV infection, with many of these methods identifying host factors involved in viral entry. Gene disruption screens identified host factors involved in sialic acid metabolism used for attachment ([@R5]; [@R12]). Vacuolar ATPases involved in endosomal acidification and other host factors facilitating fusion and uncoating were identified through small interfering RNA (siRNA) knockdown, proteomic, and overexpression screens ([@R2]; [@R20]; [@R22]; [@R26]; [@R54]). These studies also revealed previously unknown steps of FLUAV particle entry, such as the role of the aggresome in viral uncoating and the use of transportin 1 to debundle incoming RNPs prior to nuclear import ([@R2]; [@R32]). Despite these discoveries, the mechanistic details of steps occurring after fusion remain poorly understood.

Here, we conducted a screen using gene correlation analysis to identify host factors involved in FLUAV infection. Gene correlation analysis exploits naturally occurring variations in gene expression across multiple cell lines without the need to exogenously manipulate the cellular environment. Variations in cellular gene expression were used to identify factors affecting a phenotype of interest, in this case susceptibility to FLUAV infection. We identified epidermal growth factor receptor (EGFR) pathway substrate 8 (EPS8) as a pro-viral cellular cofactor during the early stages of infection. We confirmed that EPS8 enhances FLUAV gene expression and replication, whereas knockout of EPS8 reduced susceptibility to infection. Stepwise dissection of the viral entry process revealed that EPS8 specifically facilitates uncoating of the viral core. Thus, we identified EPS8 as an important component of the FLUAV uncoating process, a necessary step for successful viral genome transcription and replication.

RESULTS {#S2}
=======

Gene Correlation Analysis Identifies Putative Enhancers and Suppressors of FLUAV Replication {#S3}
--------------------------------------------------------------------------------------------

To overcome limitations of previous screening methodologies, we sought to identify both enhancers and suppressors of FLUAV replication in an unbiased manner. We used gene correlation analysis, which relied on inherent differences in gene expression among different cell lines and consequently did not require external manipulation of the cellular environment. The National Cancer Institute-60 (NCI-60) panel consists of 59 distinct cell lines with well-characterized transcriptomic profiles ([@R46]; [@R53]). The diversity of cell types and the depth of transcriptomic data permit high-confidence genome-wide correlations between cellular gene expression and infection susceptibility ([@R19]; [@R23]; [@R44]). We therefore inoculated the NCI-60 panel of cell lines with a single-cycle variant of A/WSN/1933 (H1N1, WSN) encoding GFP (WSN-GFP) ([Figure 1A](#F1){ref-type="fig"}). Using WSN-GFP, we specifically focused on host factors involved in early stages of infection up to and including viral gene expression and translation.

The permissiveness of each cell line to WSN-GFP was determined and rank-ordered relative to Madin-Darby canine kidney (MDCK) cells, which are frequently used for the propagation of FLUAV ([Figures 1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}; [Table S1](#SD2){ref-type="supplementary-material"}). We detected a broad range of susceptibility after infecting cells at an MOI of 0.2. Relative to MDCK cells, 10 cell lines were highly refractory to WSN-GFP (at least a 10-fold decrease in infection rate), and 12 cell lines were highly permissive (at least a 3-fold increase in infection rate). An association between susceptibility, cell type, tumor type, or tissue of origin was not obvious. MCF7 breast tumor cells were the most refractory cell line, with a normalized infection rate of only about 3%, whereas T-47D cells, another breast tumor cell line, were the most susceptible, with an infection rate of approximately 1,300%. These data were highly reproducible with a strong correlation between results from two independent replicate screens ([Figure S1A](#SD1){ref-type="supplementary-material"}). To ensure that the assay captured the full dynamic range of susceptibility, especially for the highly resistant cell lines, the screen was repeated at an MOI of 2 ([Figure S1B](#SD1){ref-type="supplementary-material"}). Similar infectivity trends were detected at both MOIs, although the upper limit of the assay was reached for multiple cell lines at the higher MOI, at which effectively all cells were infected ([Figures 1C](#F1){ref-type="fig"} and [S1C](#SD1){ref-type="supplementary-material"}). The number of infected cells increased at the higher MOI for most of the resistant cell lines, indicating that these cell lines are not completely refractory to FLUAV infection ([Figure S1D](#SD1){ref-type="supplementary-material"}).

The broad distribution of infectivity across the NCI-60 cell panel suggested that cell-intrinsic differences affected susceptibility to FLUAV infection. To identify cellular factors affecting FLUAV susceptibility, we calculated linear pairwise correlation coefficients between host gene expression within the NCI-60 panel of cell lines and susceptibility to infection using the COMPARE algorithm ([@R37]). We identified top hits for putative enhancers or suppressors of FLUAV infection on the basis of their strong correlation scores ([Figure 1D](#F1){ref-type="fig"}; [Table S2](#SD3){ref-type="supplementary-material"}). Host genes identified as putative enhancing factors exhibited expression patterns that paralleled susceptibility to infection, yielding a positive correlation score. Conversely, expression of host genes identified as putative suppressive factors was inversely related to susceptibility, resulting in a negative correlation score. Notably, some of our strongest hits for suppressors of FLUAV infection were the interferon-inducible transmembrane proteins (IFITMs). IFITM1, IFITM2, and IFITM3 were previously characterized as potent inhibitors of FLUAV infection, providing confidence in our approach ([Figure 1D](#F1){ref-type="fig"}; [@R3]). Most other candidate genes, including EPS8, were not previously associated with FLUAV susceptibility, revealing that gene correlation analysis can identify new host factors that regulate FLUAV infection.

EPS8 Enhances FLUAV Gene Expression and Titers {#S4}
----------------------------------------------

The putative enhancer with the strongest correlation score was EPS8, an adaptor protein involved in signaling via the EGFR and other pathways as well as modulating of actin dynamics ([Figure 1D](#F1){ref-type="fig"}; [@R8]; [@R14]). To validate the results of the screen and confirm a pro-viral function for EPS8, we assessed the effect of EPS8 on viral gene expression and replication. EPS8 was transiently overexpressed in HEK293T cells and infected with a replication-competent reporter version of WSN (WSN PA-Swap-2A-NanoLuc \[PASTN\]) to quantitatively measure viral gene expression ([@R49]). EPS8 overexpression increased viral gene expression during infection nearly 2-fold relative to the empty vector control ([Figure 2A](#F2){ref-type="fig"}). Endogenous and overexpressed EPS8 levels were confirmed by immunoblot. We then assayed viral titers when EPS8 was stably overexpressed in human lung epithelial A549 cells. Viral titers 24 h post-infection (hpi) were increased by more than 15-fold in stable EPS8-overexpressing cells relative to wild-type (WT) cells ([Figure 2B](#F2){ref-type="fig"}). Thus, overexpression of EPS8 enhances infection and replication in two different human cell lines, confirming the pro-viral correlation identified in the screen.

We next used CRISPR-Cas9 to generate clonal EPS8-knockout A549 cells. Sanger sequencing confirmed genotypic changes predicted to result in knockout of EPS8 in two independent clonal lines (*EPS8.1 and EPS8.2*) ([Figures S2A](#SD1){ref-type="supplementary-material"} and [S2B](#SD1){ref-type="supplementary-material"}). Immunoblotting for endogenous EPS8 revealed a dramatic reduction in EPS8 protein levels but not a complete loss in our edited clones ([Figure S2C](#SD1){ref-type="supplementary-material"}). *EPS8.1* retained about 25% of the amount of EPS8 observed in the parental cells, whereas *EPS8.2* levels were nearly undetectable. Editing occurred adjacent to the splice donor in exon 2 of *EPS8*, raising the possibility that alternative splice donors may be exploited to support the low levels of EPS8 protein expression detected ([Figures S2B](#SD1){ref-type="supplementary-material"} and [S2D](#SD1){ref-type="supplementary-material"}). These cell clones were used to further examine the importance of EPS8 during FLUAV infection.

Viral replication and gene expression were assayed in the *EPS8*-edited cells. Both *EPS8.1* and *EPS8.2* cell lines had defects in multicycle replication and viral gene expression assays. Viral titers were reduced by about 10-fold in both *EPS8*-edited lines compared with parental cells ([Figure 2C](#F2){ref-type="fig"}). Viral gene expression was reduced 4- to 5-fold in A549 cells with edited *EPS8* relative to WT cells ([Figure 2D](#F2){ref-type="fig"}). The decrease in viral gene expression was more pronounced in EPS8.2, the cell line with the lower level of EPS8 expressed. Stable complementation with EPS8 rescued viral gene expression in both edited lines ([Figure 2D](#F2){ref-type="fig"}), suggesting that the defects in gene expression were specifically due to decreases in EPS8 levels. To obtain a true knockout phenotype, *EPS8* was edited in 293 cells ([Figure S3](#SD1){ref-type="supplementary-material"}). EPS8-knockout 293 cells (*EPS8.D1*) exhibited a significant decrease in viral gene expression, which was restored by transient complementation ([Figure 2E](#F2){ref-type="fig"}). *EPS8* editing or knockout thus decreases viral gene expression in two different cell lines.

Given that both cell types exhibited similar phenotypes, we continued our investigation using the edited A549 cell lines, as these cells are of lung origin and more closely represent natural target cells during influenza virus infection. We assessed whether EPS8 affected infection with reporter variants of other influenza virus isolates. Cells were inoculated with a reporter virus encoding an avian-background RNP from A/green-winged teal/OH/175/1983 in a WSN backbone (S009 SRK PASTN; H2N1) or a reporter version of A/California/04/2009 (CA04 PASTN; H1N1). We also infected *EPS8*-edited cells with the influenza B virus (FLUBV) B/Brisbane/60/2008 (B/Brisbane PASTN) ([Figure 2F](#F2){ref-type="fig"}). Consistent with the results obtained using WSN, editing of *EPS8* reduced viral gene expression for the influenza A strains S009 SRK PASTN and CA04 PASTN. Interestingly, *EPS8* editing did not affect B/Brisbane PASTN gene expression ([Figure 2F](#F2){ref-type="fig"}). We explored infection specificity further by assessing the relative infection rates of A549 cells overexpressing EPS8 in response to challenge by diverse viruses ([Figure S4](#SD1){ref-type="supplementary-material"}). EPS8 expression levels did not alter infection rates of Marburg virus (MARV) or Junín virus (JUNV). In contrast, EPS8 overexpression caused decreased Ebola virus (EBOV), Venezuelan equine encephalitis virus (VEEV), and Rift Valley fever virus (RVFV) infection rates. Hence, altering EPS8 expression does not generically affect viral replication. Together, these data confirm that EPS8 acts as a pro-viral host factor during FLUAV infection and exhibits specific effects on cell infectivity depending on the virus.

EPS8 Functions Post-fusion but before Viral Gene Expression during FLUAV Infection {#S5}
----------------------------------------------------------------------------------

The structure of the NCI-60 screen and our data indicated EPS8 functions in early stages of FLUAV replication. We therefore conducted a series of experiments to determine where in the viral replication cycle EPS8 functioned to enhance infection ([Figure 3A](#F3){ref-type="fig"}). We first assessed whether EPS8 affects infection through a mechanism that directly affects viral polymerase activity. Polymerase activity was reconstituted in the absence of infection by expressing the heterotrimeric viral polymerase subunits PA, PB1, and PB2, nucleoprotein (NP), and a vRNA-like reporter encoding firefly luciferase. Polymerase activity was not statistically different in the presence or absence of exogenous EPS8 ([Figure 3B](#F3){ref-type="fig"}). Immunoblotting confirmed high levels of exogenously expressed EPS8. Similarly, polymerase activity was indistinguishable when assays were performed in EPS8-knockout or complemented 293 cells ([Figure S5A](#SD1){ref-type="supplementary-material"}). These findings establish that EPS8-mediated enhancement of viral gene expression is not due to direct impacts on the viral polymerase but rather an upstream step in the early stages of infection.

We probed each successive step that occurs early in the infectious cycle, beginning with viral attachment. WT or edited A549 cells were incubated with bioluminescent virions (PASN) that package nanoluciferase into the viral particle ([@R50]). Cells were incubated at 4°C to enable binding but prevent internalization of virions, and luciferase activity was assayed from the bound virions. No statistical difference was found between the amount of virus bound to WT and both *EPS8*-edited cell lines, indicating that EPS8 is not necessary for FLUAV attachment to cells ([Figure 3C](#F3){ref-type="fig"}). To ascertain if EPS8 affects HA-mediated entry or the fusion process, we infected cells with FLUAV encoding a different entry protein, FVG-R, a recombinant virus expressing vesicular stomatitis Indiana virus glycoprotein (VSIV-G) instead of HA ([@R13]). Viral gene expression decreased in *EPS8*-edited cells infected with FVG-R compared with WT cells ([Figure 3D](#F3){ref-type="fig"}). This observed decrease in viral gene expression was similar to the decrease demonstrated during infection with bona fide FLUAV ([Figures 2D](#F2){ref-type="fig"} and [2E](#F2){ref-type="fig"}) and suggests that EPS8 does not specifically target HA-mediated entry.

Following attachment and entry, FLUAV traffics in an endosome that undergoes acidification, which results in fusion of the endosomal and viral membranes. The function of EPS8 during endosomal acidification and fusion was tested using an acid bypass assay. Acid bypass replaces the canonical entry route with fusion of viral and plasma membranes at the cell surface, depositing vRNPs into the cytoplasm where subsequent steps of infection then proceed as usual ([@R2]; [@R29]). As in the attachment assay, virions bound to the surface of WT or edited cells at 4°C to synchronize infection. Cells were shifted to 37°C and transiently held at acidic conditions (pH 5.0) to initiate fusion at the cell surface or held at physiological conditions (pH 7.4) permitting canonical entry to proceed as a control. *EPS8* editing resulted in a decrease in viral gene expression when infections were initiated at physiological pH ([Figure 3E](#F3){ref-type="fig"}), consistent with prior data showing defects in gene expression during unsynchronized infections ([Figures 2D](#F2){ref-type="fig"} and [2E](#F2){ref-type="fig"}). Bypassing canonical entry by treating cells with acidic conditions did not restore viral gene expression in the edited cells ([Figure 3E](#F3){ref-type="fig"}), indicating that EPS8 does not function during endosomal acidification. Control experiments showed that the low-pH treatment used in our bypass assay ablates infectivity of cell-free virions ([Figure S5B](#SD1){ref-type="supplementary-material"}), indicating that viral gene expression observed in the bypass assays results from fusion at the plasma membrane and not endocytic uptake of residual virus that failed to fuse. Although indirect measures, neither acid bypass nor VSIV-G-mediated entry restored infectivity. Both of these entry pathways are distinct from canonical HA-mediated entry, suggesting EPS8 is unlikely to function at the discrete step of fusion. Together, these data establish that the effects of EPS8 during FLUAV infection are independent of virion attachment, endosomal entry, and HA-mediated fusion.

EPS8 Is Crucial for Viral Uncoating {#S6}
-----------------------------------

Our line of experimentation indicated EPS8 functions at a step following release of the viral core into the cytoplasm but before viral gene expression. Therefore, we considered whether EPS8 facilitates viral uncoating. This process can be quantified by visualizing the redistribution of punctate matrix protein (M1) staining of intact particles to diffuse staining of M1 released throughout the cytosol ([Figures 4A](#F4){ref-type="fig"} and [S5A](#SD1){ref-type="supplementary-material"}; [@R1]). WT and *EPS8*-edited cells were synchronously infected, and M1 localization was quantified at various times post-inoculation. As expected, most M1 staining was punctate in WT cells early in infection and then became diffuse at 1.5 hpi ([Figure 4B](#F4){ref-type="fig"}). By contrast, uncoating was greatly delayed in both cell lines in which *EPS8* was edited. Diffuse M1 staining was detected in only 10%--15% of *EPS8*-edited cells at 1.5 hpi compared with successful uncoating in almost all WT cells at the same time point. Immediately following fusion, viral cores are disassembled by the aggresome on the endosomal surface ([@R2]). Co-precipitations were used to probe how EPS8 might function during this period. Synchronized infections were initiated on *EPS8-edited* cells stably complemented with WT EPS8. NP specifically co-precipitated with EPS8 ([Figure 4C](#F4){ref-type="fig"}). These data suggest EPS8 physically interacts with incoming viral cores, possibly through interactions with NP, the viral polymerase, M1, or bridged by cellular uncoating partners. Our results implicate EPS8 as an important host factor during viral uncoating.

Uncoating releases vRNPs into the cytosol, where they are subsequently imported into the nucleus prior to viral gene expression. The defects in uncoating we detected in *EPS8*-edited cells predict that these cells should also exhibit delayed nuclear import. To test this possibility, we again used synchronized infections and immunofluorescence to examine the subcellular localization and kinetics of vRNP nuclear import over time. Staining for NP, the major protein component of vRNPs, revealed characteristic cytoplasmic localization of incoming vRNPs early during infection followed by distinct nuclear localization ([Figure 4D](#F4){ref-type="fig"}). Discrete cytoplasmic and nuclear localizations of vRNPs were also detected in *EPS8-edited* cells ([Figure S5B](#SD1){ref-type="supplementary-material"}). Nuclearlocalized vRNPs were detected in WT cells as early as 1.5 hpi, and the number of cells with nuclear vRNP staining increased over time, consistent with the timing of viral uncoating reported above ([Figure 4E](#F4){ref-type="fig"}). Cells lacking WT levels of EPS8, however, exhibited significantly delayed kinetics of nuclear import. Compared with WT cells, import rates in *EPS8*-edited cells were delayed by 1 h. This trend continued until 3.5 hpi when import in edited cells finally matched that of WT cells ([Figure 4D](#F4){ref-type="fig"}). Although import was delayed in edited cells, it followed a similar trajectory to WT cells once initiated, suggesting that vRNP import was not directly altered by changes to EPS8 expression. Experiments were repeated in the presence of cycloheximide to test whether the nuclear localization signal captured incoming vRNPs or required de *novo* synthesis of NP. Similar localization of vRNPs into the nucleus was detected when infection progressed in the presence of cycloheximide, even if signal intensity was reduced ([Figure S6C](#SD1){ref-type="supplementary-material"}). Furthermore, as before, *EPS8*-edited cells exhibited delayed kinetics for NP nuclear localization. Thus, defects in uncoating ([Figure 4B](#F4){ref-type="fig"}) result in delayed nuclear import ([Figure 4E](#F4){ref-type="fig"}) and ultimately a reduction in viral gene expression ([Figure 2D](#F2){ref-type="fig"}), reinforcing the conclusion that EPS8 is a key component of the cellular machinery used for viral uncoating.

DISCUSSION {#S7}
==========

Through gene correlation analysis, we conducted an unbiased genome-wide screen to identify host factors that have a functional impact on early stages of FLUAV replication. Our highest confidence pro-viral candidate was EPS8, a cytoplasmic protein involved in EGFR signaling and regulation of actin dynamics. We showed that EPS8 expression enhanced viral gene expression and titers, whereas loss of WT EPS8 caused defects in gene expression and viral replication. Stepwise investigation of the early stages of infection revealed that EPS8 functions independent of virion attachment, endosomal acidification, or HA-dependent fusion. Rather, EPS8 specifically functioned during the uncoating of the incoming viral cores. Defects in viral uncoating slowed the kinetics of vRNP nuclear import in *EPS8*-edited cells, corresponding with the overall delay in viral gene expression and replication in these cells. These data establish EPS8 as a cofactor important for viral uncoating during FLUAV infection.

The host factors used during FLUAV uncoating are not yet fully understood. Uncoating begins in the maturing endosome, where the drop in pH opens the M2 ion channel in the viral membrane ([@R38]). The influx of potassium ions and protons into the virion interior initiates conformational changes that relax interactions between the matrix protein M1 and vRNPs, making the core competent for uncoating and disassembly of the RNP bundle ([@R48]). Following fusion of the viral and host membranes, the core requires further processing to fully disassemble. Unanchored ubiquitin chains packaged within the virion help activate the cellular aggresome on the late endosomal surface where mechanical forces have been proposed to accelerate uncoating and release of vRNPs into the cytosol, followed by debundling of vRNPs by cellular transportin 1 ([@R2]; [@R32]). Our data now implicate EPS8 as another host factor important during these later stages of uncoating.

EGFR was previously implicated in FLUAV entry during virion internalization, and another EPS protein, EPS15, has been shown to play a role in regulating EGFR levels and endosome maturation during FLUAV uncoating ([@R10]; [@R11]). Our data, however, indicate that the role of EPS8 during FLUAV entry is divorced from its role in EGFR signaling. Unlike EPS15, loss of EPS8 did not alter levels of EGFR on A549 cells ([Figure S7A](#SD1){ref-type="supplementary-material"}). EPS8 was important for viral entry in both EGFR-positive A549 cells and EGFR-negative 293 cells ([Figure S7A](#SD1){ref-type="supplementary-material"}; [@R55]). Finally, complementation of *EPS8-edited* cells with EPS8 lacking the EGFR binding domain (EPS8ΔEGFR) ([@R6]) rescued viral gene expression, possibly even better than WT EPS8 ([Figure S7B](#SD1){ref-type="supplementary-material"}). These independent lines of experimentation suggest EPS8 function during viral uncoating is independent of EGFR signaling. EPS8 is also involved in modulating actin dynamics ([@R14]). Actin has been implicated in the movement of virion-containing endosomes immediately after virion internalization and also plays a role in the discrete steps post-fusion but before uncoating is completed ([@R2]; [@R21]). A role for actin during post-fusion uncoating is the same step where our data revealed EPS8 functions, raising the possibility that the ability of EPS8 to engage and modulate actin dynamics is important for uncoating.

Although cells lacking EPS8 have decreased FLUAV gene expression, that was not the case during FLUBV infection. FLUAV and FLUBV are structurally similar, and it is tempting to generalize that the replication cycle is largely the same for the two viruses. Like FLUAV, FLUBV uses receptor-mediated endocytosis for entry ([@R47]). Acidification of the FLUBV virion interior is facilitated by viral membrane protein and proton channel BM2, a FLUAV M2 homolog ([@R34]). FLUBV undergoes uncoating after fusion of viral and endosomal membranes, but many of the details of FLUBV uptake and uncoating are still unknown. Interestingly, cellular immune responses to FLUBV infection differ from those to FLUAV infection ([@R16]; [@R25]). Therefore, host processes involved in other steps of FLUBV infection may possibly also differ, as suggested by the discordant importance of EPS8 for FLUAV and FLUBV.

We also considered the possibility that other viruses using receptor-mediated endocytosis or similar internalization pathways could be affected by EPS8. A panel of RNA viruses using diverse cellular receptors and entry mechanisms was used to infect A549 cells overexpressing EPS8 ([Figure S4](#SD1){ref-type="supplementary-material"}). No obvious trends or associations with viral families or entry pathways were noted. Nonetheless, these results indicate that EPS8 enhancement of infection is specific to certain viruses, and the multifunctional nature of EPS8 may impart an anti-viral function for other viruses. In summary, our gene correlation analysis identified both pro- and anti-viral host factors with a functional impact on early stages of FLUAV replication without requiring artificial manipulation of the cellular environment. Through interrogation of early steps of FLUAV infection, we established EPS8 as a previously uncharacterized cofactor facilitating FLUAV uncoating.

STAR★METHODS {#S8}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S9}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Andrew Mehle (<amehle@wisc.edu>). All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S10}
--------------------------------------

### Cell lines {#S11}

Authenticated stocks of 293T, A549, and MDCK cells were purchased from the American Type Culture Collection (ATCC). Parental and edited 293 cells were obtained from Synthego. MDCK-HA cells were a gift from P. Palese ([@R27]). These cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS).The NCI-60 cell lines are a panel of 59 human breast, central nervous system, colon, lung, melanoma, ovarian, renal, and prostate cancer cell lines ([@R52]). The NCI-60 panel was obtained from the US National Cancer Institute's Developmental Therapeutics Program (NCI DTP), Fort Detrick, Frederick, MD, USA. All NCI-60 panel cell lines were grown in Roswell Park Memorial Institute-1640 (RPMI-1640) medium supplemented with 10% heat-inactivated FBS. All cells were grown at 37°C with 5% CO~2~ and were regularly tested and verified free of mycoplasma contamination using MycoAlert (Lonza).

### Viruses {#S12}

Influenza A virus (FLUAV) strain H1N1 A/WSN/33 (WSN) was propagated in MDCK cells. The recombinant influenza A reporter viruses WSN PASTN ([@R49]), A/California/04/2009 PASTN (H1N1, CA04 PASTN) ([@R17]), WSN PASN ([@R50]), WSN with the polymerase from A/green-winged teal/ OH/175/1983 (H2N1) encoding PB2 S590/R591/K627 (S009 SRK PASTN), B/Brisbane/60/2008 (B/Brisbane) PASTN, and FVG-R ([@R13]) were rescued using the influenza virus reverse genetics system and prepared as previously described. WSN PASN was further purified by centrifugation through a 20% sucrose cushion to remove contaminating luciferase present in the media ([@R50]). WSN-GFP was amplified and titered on HAMDCK cells ([@R27]).

Multicycle replication infections were performed by inoculating A549 cells at a multiplicity of infection (MOI) of 0.01 using virus diluted in virus growth medium (VGM) (DMEM supplemented with penicillin/streptomycin, 25 mM HEPES, 0.3% BSA) with 0.25 μg/ml TPCK-trypsin. Supernatants were collected at indicated times and titered by plaque assay on MDCK cells ([@R30]) or by a Nano-Glo viral titer assay by inoculating MDCK cells with WSN PASTN and measuring luciferase activity ([@R18]; [@R49]).

Viral gene expression was measured by infecting cells with PASTN viruses. Virus was diluted in VGM with 0.25--0.5 μg/ml TPCK-trypsin for A549 cells or Opti-MEM I medium supplemented with 2% FBS for 293T and 293 cells. Viral gene expression was measured 8 hpi using a Nano-Glo luciferase assay kit (Promega).

Viral attachment was quantified by inoculating A549 cells with PASN. Purified virus was diluted in VGM with 0.25 μg/ml TPCK-trypsin, applied to cells for 45 mins at 4°C, and removed. Cells were washed with cold VGM and bound virions were detected by performing a Nano-Glo assay.

FVG-R infections were performed by inoculating A549 cells with virus diluted in Opti-MEM I medium supplemented with 0.2% FBS. Viral gene expression was measured 8 hpi using a *Renilla* luciferase assay system (Promega).

Infections with JUNV (Romero), EBOV, and MARV (Ci67) and infections with RVFV (ZH501) and VEEV (IC-SH3) were conducted under Biosafety Laboratory 4 and 3 conditions, respectively. Cells in 96-well format (30,000 cells per well) were infected at the indicated MOIs. After 1 hour, the inocula were removed, cells were washed with PBS, and replenished with fresh growth medium. VEEV and RVFV-infected plates were fixed in formalin 20 hours post-inoculation. All other infected plates were fixed 48 hours post-inoculation. Antigen staining and high-content quantitative image-based analysis were performed as previously described ([@R39], [@R40]).

METHOD DETAILS {#S13}
--------------

### NCI-60 screen and COMPARE analysis {#S14}

NCI-60 cell lines were seeded by groups of cell origin at 3 × 10^4^ cells per well in 96-well plates and grown overnight. Cells were infected with WSN-GFP at MOIs 0.2 and 2. At 3 hours post-inoculation, the cells were washed with RPMI-1640 medium and fresh growth medium was added. WSN-GFP expression was measured by fluorescence microscopy 24 hours post-inoculation. Cells were fixed with 4% paraformaldehyde, and nuclei were stained with Hoechst 33342. WSN-GFP virus expression was detected by the Operetta-High Content Imaging System (PerkinElmer Inc.), and the percentage of GFP-positive cells were analyzed by Harmony4.1 software (PerkinElmer Inc.). WSN-GFP expression was evaluated by the flow cytometry (BD Biosciences, LSRFORTESSA) 24 hours post-inoculation. All infections were performed in triplicate, and two biological replicates performed for each MOI condition. Both approaches yielded similar results, and infectivity for each cell line was rank-ordered relative to MDCK cells. The relative infectivity of each cell line was log~2~-transformed and used as input for the COMPARE algorithm ([@R37]).

### Knockout and stable expression of EPS8 {#S15}

The *EPS8* locus was edited in A549 cells by lentiviral expression of CRISPR/Cas9 components. Vesicular stomatitis Indiana virus (VSIV) glycoprotein G-pseudotyped lentivirus was generated by transfecting 293T cells with the plasmids psPAX2, pMD2.G, and pLentiCRISPR (Addgene 52961; [@R42]) modified to encode a single-guide RNA (sgRNA) targeting *EPS8* (5′-TCAAC TTACTTCATCTGAGA-3′, [Figure S2](#SD1){ref-type="supplementary-material"}). A549 cells were transduced with this virus, placed under puromycin selection (0.5 μg/ml), and single cells were cloned. Pooled 293 cells edited at the *EPS8* locus were created by Synthego by transfecting cells with Cas9 RNPs containing an sgRNA targeting exon 5 (5′-GCACTTGACTACCTTTGTCC-3′) ([Figure S3](#SD1){ref-type="supplementary-material"}). 293 cells were single cell cloned. Edited alleles in both cell types were identified by PCR amplification of the locus, Sanger sequencing of the products, and inference of CRISPR edits (ICE) analysis ([@R15]) ([Figures S2A](#SD1){ref-type="supplementary-material"}, [S2B](#SD1){ref-type="supplementary-material"}, [S3A](#SD1){ref-type="supplementary-material"}, and [S2B](#SD1){ref-type="supplementary-material"}). Knockouts predicted by ICE analysis were assessed by immunoblot. Stable expression of EPS8 in cells was achieved by lentivirus gene delivery. The gene delivery vector pLX304-EPS8 was purchased from DNASU (HsCD00420355) and encodes the 822 amino acid splice variant (NCBI XP_024304650). pLX304-EPS8ΔEGFR was created by modifying pENTR223-EPS8 (DNASU HsCD00505776; ([@R45])) and subsequent Gateway recombination into pLX304 (Addgene 25890). Virus was produced by transfecting 293T cells with plasmids pLX304-EPS8 or pLX304-EPS8ΔEGFR, psPAX2, and pMD2.G. Wild-type and *EPS8*-edited A549 cells were transduced with these viruses and selected with blasticidin to obtain cells stably expressing EPS8 constructs.

### Polymerase activity assay {#S16}

293T or 293 cells were transfected with plasmids encoding WSN PA, PB1, PB2, and NP, a vNA-luciferase reporter, a *Renilla* luciferase control reporter, and EPS8 or an empty vector using TransIT-2020 (Mirus). Firefly luciferase and *Renilla* luciferase activity were assayed 24 hours post-transfection for 293T cells and 48 hours post-transfection for 293 cells. Firefly luciferase (FF) was normalized to *Renilla* luciferase (RLuc) within each sample. Expression of EPS8 was determined by immunoblot of cell lysates.

### Acid bypass assays {#S17}

Acid bypass with WSN PASTN was performed as described ([@R29]; [@R33]). Wild-type and *EPS8*-edited A549 cells were inoculated at an MOI of 0.1 with virus diluted in VGM with 0.25 μg/ml TPCK-trypsin for 1 hour at 4°C. The inoculum was removed and cells were washed with cold Dulbecco's phosphate-buffered saline (DPBS). Inoculated cells were then either treated with 20 mM HEPES, pH 7.4 in 154 mM NaCl or 50 mM citrate, pH 5.0 in 154 mM NaCl for 45 s at 37°C. The inoculum and treatment buffer were removed and cells were washed with room temperature DPBS. Pre-warmed DMEM supplemented with 10% heat-inactivated FBS was added to the cells, infection progressed at 37°C for 8 hours, and viral gene expression was measured by a Nano-Glo assay.

### Immunofluorescence assays {#S18}

Wild-type and *EPS8-edited* A549 cells were grown on coverslips and inoculated with WSN at an MOI of 5 in VGM with 0.25 μg/ml of TPCK-trypsin for 1 hour at 4°C. Warm VGM was added to the cells and infection progressed for the indicated length of time at 37°C. Infection was also done in the presence of 1 mM cycloheximide at an MOI of 25 for detection of viral RNPs. Cells were fixed with 4% paraformaldehyde in DPBS for 20 minutes at room temperature, permeabilized with 0.1% Triton-X in 0.1 M glycine for 5 minutes at room temperature, and blocked in 3% BSA in DPBS overnight at 4°C. Cells were incubated sequentially with primary and secondary antibodies diluted in 3% BSA in DPBS: α-M1 (19 μg/ml) and chicken α-mouse AlexaFluor 594 (2 μg/ml); or α-RNP (1:1000) and donkey α-goat AlexaFluor 488 (2 μg/ml). Coverslips were mounted using mounting medium with 4',6-diamidino-2-phenylindole (DAPI) stain (Vector Laboratories, H-1200) and imaged using 20X and 40X objectives on an EVOS FL Auto (ThermoFisher). For M1 staining, a minimum of 100 M1-positive cells at 1.5 hpi were counted across 10 random fields of view for each condition in 2 separate biological replicates. Similar quantification was performed at 1 hpi, although fewer M1-positive cells were present for all cell types. RNP localization was quantified by assessing a minimum of 100 cells across 10 random fields of view for each time point in each cell type across 3 separate biological replicates. Images were batch processed using ImageJ for quantification ([@R43]). Representative images for cytoplasmic and nuclear RNP staining were batch-processed separately to show staining distribution.

### EPS8 co-immunoprecipitations {#S19}

Interactions between EPS8 and incoming RNPs was investigated in *EPS8.1* A549 cells stably complemented with EPS8-V5. Cells were inoculated with WSN at an MOI of 25 diluted in cold VGM. Infections were synchronized by inoculating cells at 4°C for 1 hour. Warm VGM was added to the cells and infection progressed for 2.5 hours at 37°C. Cells were washed with cold PBS and lysed in co-IP buffer (50 mM Tris pH 7.4, 150 mM NaCl, 0.5% NP-40) supplemented with protease inhibitors. Lysates were clarified and subjected to immunoprecipitation with 1 μg anti-V5 antibody or control rabbit IgG. Immune complexes were captured with protein A agarose resin, washed extensively with co-IP buffer, eluted, and analyzed by anti-RNP immunoblot to probe for NP.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S20}
---------------------------------------

Each assay was performed in technical triplicate or quadruplicate and represents at least three independent biological replicates with the exception of the immunofluorescence assays which represent at least two biological replicates. Mean and standard deviation were calculated, and statistical significance was tested using a two-tailed Student's t test with unequal variance for pairwise comparison or a one-way ANOVA with a Tukey's honestly significant difference (HSD) post hoc analysis for multiple comparisons.

DATA AND CODE AVAILABILITY {#S21}
--------------------------

The source data for [Figure 1](#F1){ref-type="fig"} in the paper are available in [Table S1](#SD2){ref-type="supplementary-material"}.
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![Gene Correlation Analysis Identifies Putative Enhancers and Suppressors of FLUAV Replication.\
(A) Experimental workflow for NCI-60 screen. NCI-60 cell lines were inoculated with FLUAV encoding GFP, infections were visualized by fluorescence microscopy and quantified by flow cytometry at 24 hpi, and data were normalized to control MDCK cells inoculated in parallel.\
(B) Infectivity at an MOI of 0.2 was determined relative to MDCK cells (mean of n = 3 ± SD). Images of highly resistant (MCF7) and hypersensitive (T-47D) infected cell lines are shown compared with the control MDCK cells. Data are representative of two biological replicates.\
(C) Pairwise comparison of replicate NCI-60 screens performed at an MOI of 0.2 or 2 (mean of n = 3 ± SD; *r*~*s*~, Spearman's correlation coefficient).\
(D) COMPARE analysis of MOI 0.2 infectivity data identified top hits for putative pro-viral and anti-viral factors.\
See also [Figure S1](#SD1){ref-type="supplementary-material"}.](nihms-1545815-f0002){#F1}

![EPS8 Enhances FLUAV Gene Expression and Titers.\
(A) 293T cells transiently overexpressing EPS8 were infected with WSN PASTN, and viral gene expression was assayed (mean of n = 4 ± SD). EPS8 expression was confirmed by immunoblot.\
(B) A549 cells stably overexpressing EPS8 were infected with WSN (MOI 0.01), and viral titer was assayed at 24 hpi (mean of n = 3 ± SD).\
(C) *EPS8*-edited A549 cells were infected with WSN PASTN, virus was harvested at the indicated times, and titers were assessed using luciferase activity (mean of n = 3 ± SD).\
(D and E) *EPS8*-edited and complemented A549 (D) or 293 (E) cells were infected with WSN PASTN to assay viral gene expression (mean of n = 4 ± SD). EPS8 expression was confirmed by immunoblot.\
(F) Viral gene expression was assayed in *EPS8-edited* cells infected with S009 SRK PASTN, CA04 PASTN, or B/Brisbane PASTN (mean of n = 4 ± SD).\
\*p \< 0.05 and \*\*p \< 0.01; ns, not significant. (A) and (B) were analyzed using Student's two-tailed t test, unequal variance. Multiple comparisons were made in (C)--(F) using a one-way ANOVA with post hoc Tukey honestly significant difference (HSD) test compared with WT A549 cells. All data are representative of three biological replicates. See also [Figures S2](#SD1){ref-type="supplementary-material"}--[S4](#SD1){ref-type="supplementary-material"}.](nihms-1545815-f0003){#F2}

![EPS8 Functions Post-fusion but before Viral Gene Expression during FLUAV Infection.\
(A) Early stages in the FLUAV replication cycle were systematically probed with the indicated reagents or assays detailed in the text. PASN, bioluminescent virions; FVG-R, recombinant FLUAV expressing VSIV-G; IFA, immunofluorescence assay; PAA, polymerase activity assay.\
(B) Polymerase activity assays were performed in 293T cells expressing RNP components with or without exogenous EPS8. Firefly luciferase (FF) values were normalized to *Renilla* luciferase (RLuc) values within each sample. EPS8 expression was confirmed by immunoblot.\
(C) Virion attachment was assayed in *EPS8*-edited cells incubated with bioluminescent PASN.\
(D) WT or *EPS8*-edited cells were inoculated with FVG-R and viral gene expression was measured 8 hpi.\
(E) Acid bypass assays were performed on virions attached to WT or *EPS8*-edited cells. Cells were transiently treated with buffers at physiological pH 7.4 to initiate canonical viral entry or acidic pH 5.0 to cause fusion at the cell surface. Viral gene expression was measured 8 h after treatment.\
For all, data are mean of n = 3 ± SD. \*\*p \< 0.01; ns, not significant. (B) was analyzed using Student's two-tailed t test, unequal variance. Multiple comparisons were made in (C)--(E) using a one-way ANOVA with post hoc Tukey HSD test compared with WT A549 cells. All data are representative of three biological replicates. See also [Figure S5](#SD1){ref-type="supplementary-material"}.](nihms-1545815-f0004){#F3}

![EPS8 Is Crucial for Viral Uncoating.\
(A) A549 cells synchronously infected with WSN were stained for M1 (red) and the nucleus (blue). Representative images show punctate M1 consistent with intact viral cores and diffuse M1 staining that occurs following viral uncoating.\
(B) Quantification of diffuse staining in M1-positive cells (mean of n = 2 ± SD).\
(C) *EPS8*-edited A549 cells complemented with EPS8 were infected and lysates subjected to immunoprecipitation. Co-precipitating NP and total NP and EPS8 expression were confirmed by immunoblot.\
(D) WT A549 cells infected with WSN were stained for viral RNPs (green). Representative images show cytoplasmic RNP staining or nuclear RNP staining determined by colocalization with the nucleus (blue).\
(E) Quantification of the number of cells with nuclear RNP staining at each time point (mean of n = 3 ± SD).\
\*p \< 0.05, one-way ANOVA with post hoc Tukey HSD test compared with WT A549 cells. Scale bar, 20 μm. All data are representative of three biological replicates. See also [Figure S6](#SD1){ref-type="supplementary-material"}.](nihms-1545815-f0005){#F4}

  REAGENT or RESOURCE                                                                                                         SOURCE                               IDENTIFIER
  --------------------------------------------------------------------------------------------------------------------------- ------------------------------------ ------------------------------------------------------
  Antibodies                                                                                                                                                       
  Mouse monoclonal anti-EPS8                                                                                                  BD Biosciences                       Cat\# 610144; RRID: AB_397545
  Mouse anti-M1 HB-64                                                                                                         Yewdell et al., 1981/ATCC            M2--1C6--4R3 (HB-64)
  Goat polyclonal anti-RNP                                                                                                    BEI                                  NR-3133
  Mouse monoclonal anti-tubulin                                                                                               Sigma                                Cat\# T9026; RRID: AB_477593
  Rabbit polyclonal anti-HSP90α/β                                                                                             Santa Cruz Biotechnology             Cat\# sc-7947; RRID: AB_2121235
  Rabbit polyclonal anti-V5                                                                                                   Bethyl Laboratories                  Cat\#A190--120A; RRID: AB_67586
  Mouse monoclonal anti-EGFR clone 2A2H10                                                                                     ProteinTech                          66455--1-Ig
  Chicken polyclonal anti-mouse AlexaFluor 594                                                                                Invitrogen                           Cat \# A-21201; RRID: AB_141630
  Donkey polyclonal anti-goat AlexaFluor 488                                                                                  Invitrogen                           Cat\# A-11055; RRID: AB_2534102
  Protein A agarose                                                                                                           Sigma                                P7786
  Bacterial and Virus Strains                                                                                                                                      
  Influenza A virus: A/WSN/33 (H1N1; WSN)                                                                                     rescued for this project             N/A
  Influenza A virus: A/California/04/2009 (H1N1; CA04)                                                                        rescued for this project             N/A
  Influenza B virus: B/Brisbane/60/2008 (B/Brisbane)                                                                          rescued for this project             N/A
  Junín virus, Romero                                                                                                         USAMRIID virus stock                 23079
  Ebola virus                                                                                                                 IRF-Frederick virus stock            IRF0259
  Marburg virus, Ci67                                                                                                         USAMRIID virus stock                 18204
  Rift Valley fever virus, ZH501                                                                                              USAMRIID virus stock                 18205
  Venezuelan equine encephalitis virus, IC-SH3                                                                                USAMRIID virus stock                 17539
  WSN-GFP                                                                                                                     [@R27]                               N/A
  WSN-PASTN                                                                                                                   [@R49]                               N/A
  CA04 PASTN                                                                                                                  [@R17]                               N/A
  WSN-PASTN with viral polymerase from A/green-winged teal/ OH/175/1983 (H2N1) encoding PB2 S590/R591/K627 (S009 SRK PASTN)   This paper                           N/A
  B/Brisbane PASTN                                                                                                            This paper                           N/A
  PASN                                                                                                                        [@R50]                               N/A
  FVG-R                                                                                                                       [@R13]                               N/A
  Chemicals, Peptides, and Recombinant Proteins                                                                                                                    
  TransIT-2020                                                                                                                Mirus                                MIR 5400
  ECL Prime Western Blotting Detection Reagent                                                                                GE Healthcare                        GERPN2236
  Critical Commercial Assays                                                                                                                                       
  Nano-Glo luciferase assay kit                                                                                               Promega                              N1120
  Renilla luciferase assay system                                                                                             Promega                              E2810
  MycoAlert                                                                                                                   Lonza                                LT07--218
  Experimental Models: Cell Lines                                                                                                                                  
  Human: NCI-60 panel of cell lines                                                                                           NCI DTP (<https://dtp.cancer.gov>)   NCI Anti-Cancer Cell Line Panel
  Human: 293T                                                                                                                 ATCC                                 CRL-3216
  Human: A549, male                                                                                                           ATCC                                 CCL-185
  Human: A549 EPS8 knockouts                                                                                                  this study                           N/A
  Canine: MDCK, female                                                                                                        ATCC                                 CCL-34
  Canine: MDCK-HA                                                                                                             [@R27]                               N/A
  Human: 293                                                                                                                  Synthego                             N/A
  Human: 293 EPS8 knockouts                                                                                                   Synthego                             N/A
  Recombinant DNA                                                                                                                                                  
  Plasmid: pLX304-EPS8                                                                                                        DNASU                                HsCD00420355
  Plasmid: pLX304-EPS8 ΔEGFR                                                                                                  This paper                           N/A
  Plasmid: pENTR223-EPS8                                                                                                      DNASU                                HsCD00505776
  Plasmid: pLentiCRISPR                                                                                                       [@R42]                               Addgene 52961
  Plasmid: p3X-1T                                                                                                             [@R49]                               N/A
  Plasmid: pCAGGS-NP                                                                                                          [@R35]                               N/A
  Plasmid: pHH21-vNA-Luc                                                                                                      [@R41]                               N/A
  Plasmid: pRL-SV40                                                                                                           Promega                              E2231
  Plasmid: psPAX2                                                                                                             D. Trono                             Addgene 12260
  Plasmid: pMD2.G                                                                                                             D. Trono                             Addgene 12259
  Software and Algorithms                                                                                                                                          
  COMPARE                                                                                                                     [@R37]                               <https://dtp.cancer.gov/databases_tools/compare.htm>
  ICE                                                                                                                         [@R15]                               <https://ice.synthego.com/#/>
  ImageJ                                                                                                                      [@R43]                               <https://imagej.nih.gov/ij/>

###### Highlights

-   Gene correlation analysis identifies host factors for influenza A virus replication

-   EPS8 is a pro-viral factor for influenza A virus replication

-   Cells lacking EPS8 have delayed virion uncoating and RNP import

-   EPS8 physically associates with vRNPs during uncoating
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